Abstract:Background Salt‐sensitive hypertension is highly prevalent and associated with cardiorenal damage. Large clinical trials have demonstrated that SGLT2 (sodium‐glucose cotransporter 2) inhibitors exert hypotensive effect and cardiorenal protective benefits in patients with hypertension with and without diabetes. However, the underlying mechanism remains elusive. Methods and Results Dahl salt‐sensitive rats and salt‐insensitive controls were fed with 8% high‐salt diet and some of them were treated with canagliflozin. The blood pressure, urinary sodium excretion, and vascular function were detected. Transient receptor potential channel 3 (TRPC3) knockout mice were used to explain the mechanism. Canagliflozin treatment significantly reduced high‐salt‐induced hypertension and this effect was not totally dependent on urinary sodium excretion in salt‐sensitive hypertensive rats. Assay of vascular function and proteomics showed that canagliflozin significantly inhibited vascular cytoplasmic calcium increase and vasoconstriction in response to high‐salt diet. High salt intake increased vascular expression of TRPC3 in salt‐sensitive rats, which could be alleviated by canagliflozin treatment. Overexpression of TRPC3 mimicked salt‐induced vascular cytosolic calcium increase in vitro and knockout of TRPC3 erased the antihypertensive effect of canagliflozin. Mechanistically, high‐salt‐induced activation of NCX1 (sodium‐calcium exchanger 1) reverse mode increased cytoplasmic calcium level and vasoconstriction, which required TRPC3, and this process could be blocked by canagliflozin. Conclusions We define a previously unrecognized role of TRPC3/NCX1 mediated vascular calcium dysfunction in the development of high‐salt‐induced hypertension, which can be improved by canagliflozin treatment. This pathway is potentially a novel therapeutic target to antagonize salt‐sensitive hypertension. Nonstandard Abbreviations and Acronyms [Ca 2+ ]cyt cytosolic free calcium concentration NCX1 sodium‐calcium exchanger 1 ND normal diet SGLT2i sodium‐glucose exchanger 2 inhibitor SS Dahl salt‐sensitive rats SS‐19BN Dahl salt‐insensitive rats TRPC3 transient receptor potential channels 3 Clinical Perspective What Is New? The SGLT2 (sodium‐glucose cotransporter 2) inhibitor canagliflozin antagonizes salt‐induced hypertension in salt‐sensitive rats by directly alleviating vasoconstriction. Salt‐induced vascular transient receptor potential channel 3 upregulation results in an augmented vasoconstriction in salt‐sensitive hypertensive rats through facilitating NCX1 (sodium‐calcium exchanger 1)‐mediated vascular calcium uptake, which could be alleviated by canagliflozin. What Are the Clinical Implications? Antagonizing the interaction between transient receptor potential channel 3 and NCX1 by the SGLT2 inhibitor canagliflozin would represent a novel target to antagonize salt‐sensitive hypertension. Canagliflozin exerts its antihypertensive effect beyond its canonical effect on renal natriuresis. Cardiovascular disease has always been the biggest threat to human health. 1 Chronic vascular diseases such as hypertension and atherosclerosis are the main pathogenic factors or early pathological processes of high‐mortality diseases such as coronary heart disease, myocardial infarction, and heart failure. High salt intake not only acts as an independent risk factor for hypertension but also causes cardiovascular and renal damage. 2 , 3 High salt intake raises blood pressure (BP) through activation of the sympathetic nerve system and renin‐angiotensin system and leads to renal sodium retention. 4 Modest reduction in dietary salt intake substantially reduces cardiovascular events in the general population, but daily salt intake has remained unchanged in the past 2 decades. 5 , 6 Thus, to identify an alternative therapy for reducing t -Abstract Truncated-

Sodium-glucose exchanger 2 inhibitor canagliflozin promotes mitochondrial metabolism and alleviates salt-induced cardiac hypertrophy via preserving SIRT3 expression

An Effective Sodium-Dependent Glucose Transporter 2 Inhibition, Canagliflozin, Prevents Development of Hypertensive Heart Failure in Dahl Salt-Sensitive Rats

Canagliflozin mediates mitophagy through the AMPK/PINK1/PARKIN pathway to alleviate isoprenaline-induced cardiac remodelling

Canagliflozin Mediates Mitophagy Through the AMPK/PINK1/Parkin Pathway to Alleviate ISO-induced Cardiac Remodeling.

S-18-3: SGLT2 INHIBITOR CANAGLIFLOZIN ANTAGONIZES SALT-SENSITIVE HYPERTENSION THROUGH MODIFYING TRPC3 MEDIATED VASCULAR CALCIUM HANDLING

Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt-Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling.

Abstract 14007: Sodium-Dependent Glucose Transporters 2 Inhibition Ameliorates Obesity-Induced Metabolic Changes and Cardiomyopathy

Abstract 15090: AMP-Activated Protein Kinase Upregulates Sodium-Dependent Glucose Transporter SGLT1, Which Contributes to Cardiac Ischemia-Reperfusion Injury

SGLT1 Inhibition Attenuates Apoptosis in Diabetic Cardiomyopathy Via the JNK and P38 Pathway

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Ameliorate Metabolic Disorder and Obesity Induced Cardiomyocyte Injury and Mitochondrial Remodeling

Metabolomic Analysis of the Effect of Canagliflozin on HFpEF Rats and Its Underlying Mechanism

Reno- and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench

SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts

Canagliflozin Ameliorates Epithelial-Mesenchymal Transition in High-Salt Diet-Induced Hypertensive Renal Injury Through Restoration of Sirtuin 3 Expression and the Reduction of Oxidative Stress

Effects of canagliflozin on human myocardial redox signalling: clinical implications

SGLT1: A Potential Target for Human Ischemic and Hypertrophic Heart?

SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism

Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Cardiac Remodelling: a Systematic Review and Meta-Analysis

Sodium-glucose co-transporter 2 Inhibitors Act Independently of to Confer Benefit for Heart Failure with Reduced Ejection Fraction in Mice

Sodium-glucose cotransporter 2 inhibitor attenuates left ventricular dysfunction in post-myocardial infarction in rats via reducing cardiac mitochondrial impairment

Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy